+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Density gradient separation of autologous bone marrow grafts before ex vivo purging with 4 hydroperoxycyclosphosphamide



Density gradient separation of autologous bone marrow grafts before ex vivo purging with 4 hydroperoxycyclosphosphamide



Bone Marrow Transplantation 6(5): 321-328



We found in previous studies that the cytotoxicity of 4-hydroperoxycyclophosphamide (4-HC) toward normal and malignant cells in autologous bone marrow grafts was modulated by the variable erythrocyte content of the incubation mixture. This affected both the kinetics of engraftment and the probability of leukemic relapse. To decrease this variability in 4-HC cytotoxicity, we initiated a trial of density-gradient separation of the autografts to remove erythrocytes and other mature blood cells before the 4-HC treatment. A series of 64 consecutive patients was studied. Light-density (sp. gr. .ltoreq. 1.077 g/ml) cells were isolated in a 2-step procedure by Ficoll-diatrizoate separation of previously isolated buffy-coat cells. Overall cell recovery after buffy-coat and gradient separations was 28.9 .+-. .7% (.+-.SD). These cells were than treated with 60 .mu.g/ml of 4-HC. The erythrocyte content of the incubation mixtures averaged 0.8%, and did not predict percent CFU-GM survival after the 4-HC incubation. The variability in CFU-GM survival after the purge was less than for previous patients who received buffy-coat cells (with erythrocyte contents ranging from 4-22%) treated with 100 .mu.g/ml of 4-HC, indicating that a more uniform purge was achieved. Although the selected dose of 4-HC (60 .mu.g/ml) yielded a lower CFU-GM survival, the kinetics of engraftment did not significantly differ between the recipients of light-density or buffy-coat cells. No patient required use of a 'backup' graft because of engraftment failure.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 007184286

Download citation: RISBibTeXText

PMID: 2291993


Related references

Density-gradient separation for 4-hydroperoxycyclophosphamide purging of autologous bone marrow grafts. Progress in Clinical and Biological Research 333: 369-377, 1990

Correlation of hematologic recovery with cfu gm content of autologous bone marrow grafts treated with 4 hydroperoxycyclosphosphamide culture after cryopreservation. Bone Marrow Transplantation 4(5): 553-558, 1989

Rapid and automated processing of bone marrow grafts without Ficoll density gradient for transplantation of cryopreserved autologous or ABO-incompatible allogeneic bone marrow. Bone Marrow Transplantation 10(6): 507-513, 1992

Transferrin ricin a chain for ex vivo purging of small cell carcinoma cells from autologous bone marrow grafts. Clinical Research 38(1): 17A, 1990

A two-phase approach to B lymphocyte purging of autologous bone marrow grafts for patients with malignant lymphoma contaminated bone marrow. Progress in Clinical and Biological Research 389: 105-109, 1994

Density gradient separation of hematopoietic stem cells in autologous bone marrow transplantation. Haematologica 76 Suppl 1: 18-21, 1991

In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation. Journal of Clinical Oncology 14(10): 2791-2802, 1996

Photoradiation methods for purging autologous bone marrow grafts. Progress in Clinical and Biological Research 333: 87-102, 1990

Evaluation of parameters for purging of autologous bone marrow grafts with 4 hydroperoxycyclophosphamide. Bone Marrow Transplantation 2(SUPPL 2): 147-148, 1987

Immunomagnetic purging of bone marrow grafts for autologous transplantation in neuroblastoma. Acta Clinica Belgica 45(2): 97-106, 1990

Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma. Progress in Clinical and Biological Research 377: 71-78, 1992

Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts. Experimental Hematology 25(7): 629-637, 1997

In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation. Experimental Hematology 21(2): 311-318, 1993

Importance of cellular defense mechanisms in the photodynamic purging of autologous bone marrow grafts. Progress in Clinical and Biological Research 389: 147-154, 1994